Correction: Loss of the tumour suppressor LKB1/STK11 uncovers a leptin-mediated sensitivity mechanism to mitochondrial uncouplers for targeted cancer therapy.

Save

Correction: Mol Cancer 23, 147 (2024)

https://doi.org/10.1186/s12943-024-02061-4

Following publication of the original correspondence [1], the authors wish to extend their acknowledgements to provide a more clear and precise credit to Dr P Haramis, Dr L Mans and Dr G Gargiulo’s work that was included in their manuscript. First, they would like to thank Dr P Haramis and Dr L Mans for the work done in zebrafish and cite the data published in Dr Mans’ doctoral thesis [2] used in Figs. 1 C-F, S1B-E and S2 of the manuscript.

They also thank Dr Haramis for her original concept of exploiting the hypermetabolic phenotype of lkb1 mutant zebrafish in a synthetic lethality screen. Finally, they would like to extend their acknowledgements to Dr G Gargiulo for the analysis of the RNA-seq experiments on zebrafish performed at the Genomics Core Facility of the NKI.

Related articles

PubMed

AI-driven virtual screening platform identifies novel NSUN2 inhibitor candidates for targeted cancer therapy: a computational drug discovery approach.

The RNA cytosine-5 methyltransferase NSUN2 is an emerging therapeutic target in precision oncology, with aberrant overexpression driving tumor progression, metastasis, and therapy resistance across multiple malignancies. Despite its critical role in cancer biology, selective small-molecule inhibitors remain limited. We employed an AI-accelerated workflow to screen approximately 101 million compounds from the ZINC database using structure-based virtual screening. The AlphaFold2-predicted human NS...